Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

Company Overview - Mural Oncology plc is a clinical-stage immuno-oncology company focused on developing novel engineered cytokine therapies for various cancers [1][3] - The company is leveraging a protein engineering platform to create cytokine-based immunotherapies aimed at improving the lives of cancer patients [3] Recent Developments - Caroline Loew, Ph.D., CEO of Mural Oncology, will present at the East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST [1] - A webcast of the presentation will be available on the company's investor relations website [1] Product Pipeline - Mural Oncology's lead candidate, nemvaleukin, is currently undergoing potentially registrational trials for mucosal melanoma and platinum-resistant ovarian cancer [3]